Sunday , August 9 2020
Home / Audit and Guideline / Link For Guideline / USFDA Guideline (Chemistry, Manufacturing, and Controls (CMC))

USFDA Guideline (Chemistry, Manufacturing, and Controls (CMC))

Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products

 

Analytical Procedures and Methods Validation for Drugs and Biologics

 

Changes to an Approved NDA or ANDA (Revised) (I)

 

Changes to an Approved NDA or ANDA Questions and Answers (I)

 

CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports

 

Comparability Protocols – Chemistry, Manufacturing, and Controls Information (I)

 

Container Closure Systems for Packaging Human Drugs and Biologics (I)

 

Environmental Assessment of Human Drug and Biological Aplication

 

Environmental Assessment Question and Answer

 

Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for

 

INDs for Phase 2 and 3 Studies; Chemistry, Manufacturing, and Controls Information (I)

 

Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products — Chemistry,

 

NDAs Impurities in Drug Substances (I)

 

Non-Penicillin Beta-Lactam Risk Assessment A CGMP Framework

 

Orally Disintegrating Tablets (I)

 

PAC-ALTS Postapproval Changes – Analytical Testing Laboratory Sites (I)

 

Residual Solvents in Drug Products Marketed in the United States

 

Scale-Up and Post-Approval Changes Manufacturing Equipment Addendum

 

Submitting Documentation for the Manufacturing of and Controls for Drug Products (I)

 

Submitting Samples and Analytical Data for Methods Validation (I)

 

SUPAC Manufacturing Equipment Addendum

 

SUPAC MR Modified Release Solid Oral Dosage Forms Scale Up and Postapproval Changes

 

SUPAC-IR and MR Immediate Release and Modified Release Solid Oral Dosage Forms

 

SUPAC-IR Immediate-Release Solid Oral Dosage Forms Scale-Up and Post-Approval

 

SUPAC-MR Modified Release Solid Oral dosage from

 

SUPAC-SS – Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes

 

USFDA Guidances List 10-1-14

 

VALIDATION OF ANALYTICAL PROCEDURES and Methodology

 

Validation of Chromatographic Methods — Reviewer’s Guidance (I)

About Pharmaceutical Guidanace

Mr. Shiv Kumar is the Author and founder of pharmaceutical guidance, he is a pharmaceutical Professional from India having more than 14 years of rich experience in pharmaceutical field. During his career, he work in quality assurance department with multinational company’s i.e Zydus Cadila Ltd, Unichem Laboratories Ltd, Indoco remedies Ltd, Panacea Biotec Ltd, Nectar life Science Ltd. During his experience, he face may regulatory Audit i.e. USFDA, MHRA, ANVISA, MCC, TGA, EU –GMP, WHO –Geneva, ISO 9001-2008 and many ROW Regularities Audit i.e.Uganda,Kenya, Tanzania, Zimbabwe. He is currently leading a regulatory pharmaceutical company as a head Quality. You can join him by Email, Facebook, Google+, Twitter and YouTube

Check Also

WHO Guideline for Basic protective measures against new coronavirus and Myth busters

To prevent infection and to slow transmission of COVID-19, do the following: Wash your hands …